Montag, 19. April 2021
Navigation öffnen
Anzeige:
Vectibix
JOURNAL ONKOLOGIE – STUDIE

Adrenal Tumors - Pathogenesis and Therapy

Rekrutierend

NCT-Nummer:
NCT00669266

Studienbeginn:
September 2002

Letztes Update:
28.08.2018

Wirkstoff:
-

Indikation (Clinical Trials):
Syndrome, Pheochromocytoma, Cushing Syndrome, Adrenocortical Carcinoma, Adrenal Gland Neoplasms, Hyperaldosteronism

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
University of Wuerzburg

Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany), German Federal Ministry of Education and Research,

Studienleiter

Martin Fassnacht, MD
Principal Investigator
U of Wuerzburg

Kontakt

Studienlocations
(1 von 1)

University of Wuerzburg
97080 Wuerzburg
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Martin Fassnacht, MD
E-Mail: fassnacht_m@medizin.uni-wuerzburg.de

Stefanie Hahner, MD
E-Mail: hahner_s@medizin.uni-wuerzburg.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- adrenal tumor detected by imaging

Exclusion Criteria:

Studien-Arme

  • Tumor
    Tumor material and corresponding biosamples from patients with adrenal tumors
  • control group
    Biomaterial from patients without adrenal tumor

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren